Form 4: Select Medical CFO Receives Significant Restricted Stock Grant

Select Medical Holdings Corp.'s Chief Financial Officer, Michael F. Malatesta, was granted 75,000 shares of restricted common stock, vesting in 2028.

Summary

• Michael F. Malatesta, Chief Financial Officer of Select Medical Holdings Corp. (SEM), was granted 75,000 shares of common stock.
• The transaction date for this grant is July 29, 2025.
• The restricted stock grant vests in full on July 29, 2028, which is the third anniversary of the grant date.
• Following this transaction, Michael F. Malatesta beneficially owns 245,414 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key executive like the CFO is a positive sign of management retention and alignment with long-term shareholder interests, as the value is tied to future stock performance. It does not, however, directly reflect operational or financial performance.

Positives

• The grant of restricted stock aligns the Chief Financial Officer's interests with long-term shareholder value, as the shares vest over time and their value is tied to the company's stock performance.
• This type of equity compensation is a common tool for executive retention and motivation.

Future Outlook

The restricted stock grant is set to vest on July 29, 2028, indicating a future milestone for the executive's compensation.

Industry Context

This filing represents a standard executive compensation event within the healthcare services industry, where equity grants are a common component of remuneration packages designed to align management incentives with long-term company performance.

Comparison to Industry Standards

• Granting restricted stock to key executives like the CFO is a widely accepted practice across various industries, including healthcare, to incentivize long-term commitment and performance.
• The three-year vesting period is a common structure for such grants, comparable to practices at companies like HCA Healthcare, Universal Health Services, or Tenet Healthcare, which also utilize multi-year vesting schedules for executive equity awards to ensure sustained alignment.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial interests with the company's long-term stock performance, potentially benefiting shareholders through improved management incentives.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• The restricted stock will vest on July 29, 2028, at which point the shares will become fully owned by the Chief Financial Officer, subject to the terms of the grant.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation grant and does not provide sufficient information to alter an investment thesis. It indicates management retention and alignment but is not a catalyst for a change in stock recommendation.

Keywords

Select Medical Holdings Corp, SEM, Michael F. Malatesta, Chief Financial Officer, CFO, Restricted Stock, Equity Compensation, Insider Transaction, Form 4, Executive Compensation